



# COMPANY PRESENTATION

*A NEW ERA IN HEALTHCARE*

*April 2018*



## THIS IS A CONFIDENTIAL DOCUMENT

This presentation is not a prospectus nor an offer for securities in any jurisdiction nor a securities recommendation. The information in this presentation is an overview and does not contain all information necessary for investment decisions. In making investment decisions in connection with any acquisition of securities, investors should rely on their own examination of the assets and consult their own legal, business and/or financial advisers.

The information contained in this presentation has been prepared in good faith by G Medical Innovations Ltd (G Medical), however no representation or warranty expressed or implied is made as to the accuracy, correctness, completeness or adequacy of any statements, estimates, opinions or other information contained in this presentation.

To the maximum extent permitted by law, G Medical, its directors, officers, employees and agents disclaim liability for any loss or damage which may be suffered by any person through the use or reliance on anything contained in or omitted in this presentation.

Certain information in this presentation refers to the intentions of G Medical, but these are not intended to be forecasts, forward looking statements or statements about future matters for the purposes of the corporations act or any other applicable law. The occurrence of events in the future are subject to risks, uncertainties and other factors that may cause G Medical's actual results, performance or achievements to differ from those referred to in this presentation.

Accordingly, G Medical, its directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of the events referred to in the presentation will actually occur as contemplated.



## OUTLINE

① G MEDICAL OVERVIEW

② THE MARKET

③ PRODUCT SUITE

④ BUSINESS MODEL

⑤ MILESTONES

APPENDIXES- MARKET REVIEW: CHINA & TELCO,  
REGULATION, PATENTS, PRIZMA COMPETITION

The background image shows a doctor in a white lab coat with a stethoscope around their neck. Overlaid on this is a network diagram consisting of several circular nodes, each containing a medical cross icon. These nodes are connected by thin lines, forming a web-like structure. A large white number '1' is positioned in the upper center of the image.

# 1

OVERVIEW



## AT A GLANCE


**G Medical Innovations** is at the forefront of the digital health revolution in developing the next generation mobile technologies that will empower consumers and providers to better monitor, manage, and improve clinical and personal health outcomes.

- Founded in 2014
- Public company – traded on the ASX (GMV)
- Global Presence
- 90 Employees worldwide





## COMPANY STRUCTURE



- **G Medical Innovations Israel** – R&D and Regulatory
- **G Medical Diagnostic Services, USA** –Independent Diagnostic Testing Facility (IDTF)

- **China** – Production and local sales and marketing
- **G Medical Macedonia** - Additional R&D
- **G Medical UK** – Administration, online sales
- **G Medical Asia Limited (HK)** – Business sales hub



## THE COMPANY'S VISION

*G Medical Innovations is ushering in a new era of healthcare and wellness by utilizing its patented wireless technologies, and proprietary information technology and service platforms, to empower a new generation of consumers, patients and providers to improve quality of life by:*



ENABLING EARLY  
DETECTION



IMPROVING  
HEALTHCARE  
OUTCOMES



REDUCING  
COSTS



EXPANDING ACCESS  
TO CLINICALLY  
RELEVANT  
INFORMATION



## OUR BOARD & MANAGEMENT – EXPERIENCE & TRACK RECORD




### Strong R&D

- Over 25 years of experience in developing mobile embedded medical sensors



### Regulatory approvals

- Medical grade devices – approved following FDA and CE guidance
- Over 48 medical devices approved by FDA



### Go To Market

- Over 25 years of medical device development and commercialization



### Medical Service Model – Medical Call Centers setup and operation

- *Over 25 years of experience in international and US patients monitoring*
- *Over 5M patients monitored*





## MANAGEMENT TEAM

Established track record in commercialising medical devices

### **Dr. Yacov Geva**

#### **President & CEO**

A well-known pioneer in the industry of Medical Devices and remote monitoring services, and co-founder of LifeWatch AG (former Card Guard AG and Card Guard Scientific Survival Ltd.). Successfully led LifeWatch to an IPO. Dr. Geva holds a B.Sc in Mechanical and Nuclear Engineering, a Ph.D. (with honors) in Business Administration from the International School of Management, Paris and an honorary doctorate from Oxford Brooks University. Dr. Geva is also a senior member of the royal society of medicine in the UK (RSM).

### **Mr. Rafi Heumann**

#### **President & COO**

Mr. Heumann has over 20 years of experience in Hi-tech, mHealth, operations and services industries. He brings with him advanced skills in strategic planning, international negotiations and business development, and directing complex projects. Mr. Heumann has business management education from Bar-Ilan University, Israel.

### **Mr. Kobi Ben-Efraim**

#### **CFO**

An experienced and senior CFO of global companies with more than 20 years' experience in the finance and accounting domain. He has served in Israeli high tech companies including DSPC Group (a NASDAQ-traded company) and El-Op. Mr. Ben-Efraim holds a B.A. in Economics and Accounting from Tel Aviv University, and is a Certified Public Accountant (IL).

### **Mr. Louis Antoniou**

#### **President & Corporate Business Development**

Mr. Antoniou is considered an industry pioneer with history of innovative program evolution and cutting-edge product launches. He has diverse industry sales channel experience including telecommunications, electronics, automotive, distribution and information technology. Mr. Antoniou has a bachelor's degree in economics from the University of Bridgeport.

### **Mr. Mark Bogart**

#### **President G Medical USA**

Mr. Bogart has a track record of over 20 years as an executive in the medical device and healthcare services. He is a subject matter expert in mHealth, wireless telemedicine and remote monitoring, and brings also substantial experience in strategic business development and managing and directing sales force teams.

### **Mr. Benny Tal**

#### **VP, R&D**

Mr. Tal brings over 40 years of expertise in Electronics Development, Engineering and Operations. He has led R&D, engineering, and operation teams for OEM/ODM products. Mr. Tal holds a B.Sc. in Electrical Engineering and Computers and an MBA from Ben-Gurion University, Israel.

### **Mr. Nir Geva**

#### **CTO & Business Development**

Mr. Geva has over 17 years of experience in the Hi-Tech and Medical Device industry. A former CTO and strategic projects manager at LifeWatch Technologies, he has broad knowledge on project management and manufacturing of medical devices. Mr. Geva wrote over 15 patents related to Medical Devices, Remote Patients Monitoring and IoT. He holds a BSc. in Mechanical Engineering from the Technion in Haifa and an Executive MBA from Kellogg school of management, (Northwestern University in Chicago).



## BOARD OF DIRECTORS

Diverse international Board, with expertise in growth companies

### Dr. Kenneth R. Melani

#### Chairman of the Board

Dr. Melani has over 30 years' experience in the healthcare industry as a provider, supplier and insurer. He has started seven successful for-profit health services businesses and has served in various critical business roles including CEO, Chief Medical Officer, and Strategy and Business Development.

During his tenure as President and CEO of Highmark Inc. in 2003 to 2012, he grew the company into one of the largest and most diversified healthcare companies in the United States, serving over 32 million individuals. He has been an investor in numerous pre- IPO investments since 1985 and was instrumental for several successful IPOs in Switzerland.

### Dr. Shuki Gleitman

#### Non Executive Director

Dr. Gleitman is the Chairman of the Guangzhuo Israel Biotech Fund, Chairman of the Board of Directors of Capital Point Group, a Board member and Chairman of the audit and financial committees of Elbit Systems (NASDAQ, TLV traded), Chairman of the YoYa Group, Senior Advisor to the World Bank (national policy for innovation) and Senior Strategy Advisor to Serbia Innovation Fund. Prior to this, Dr. Gleitman was the Chief Scientist and Director General of Israel's Ministry of Industry and Trade, where he managed all of the Israeli Government technological programs.

### Dr. Yacov Geva

#### President & CEO Executive Director

### Mr. Louis Antoniou

#### President & Corporate Business Dev't Non Executive Director

### Dr. Brendan de Kauwe

#### Non Executive Director

Dr. de Kauwe Dr de Kauwe studied a Bachelor of Science and Bachelor of Dental Surgery from the University of Western Australia. He also holds a Post Graduate Diploma in Applied Finance, majoring in Corporate Finance.

He is a Director of Otsana Capital, a corporate advisory firm in Western Australia experienced in corporate restructuring and recapitalisations, mergers and acquisitions, IPO/RTO transactions and capital markets.

He is currently Director of Race Oncology Ltd (ASX:RAC) and Ookami Ltd (ASX:OOK).

### Mr. Urs Wettstein

#### Non Executive Director

Mr Wettstein has an accounting, auditing and taxation background in Switzerland, having founded his own accounting firm and also worked with Coopers and Lybrand AG in Zurich. He has been an advisor and investor in numerous pre- IPO investments since 1985 and was instrumental for several successful IPOs in Switzerland.

### Mr. Sam Skontos

#### Non Executive Director

Sam Skontos has a career spanning 28 years in sales and marketing in Australia, New Zealand and Asia. He holds a Bachelor of Engineering (Electrical) from the University of NSW and has extensive experience in the technology and communications sectors.

### Mr. Ashley Krongold

#### Non Executive Director

Mr Krongold is the CEO of the Krongold Group, a third-generation, family-run group of companies based in Melbourne with businesses spanning various industries. He is a Non-executive Director of Weebit Non Ltd (ASX:WBT) and Dotz Nano Limited (ASX:DTZ). Ashley is also a founding General Partner of global equity crowd-funding platform, OurCrowd.

# 2



## THE MARKET



## THE GLOBAL HEALTHCARE CHALLENGE

### RISING COMPLEXITY AND COST

Healthcare spending as % of GDP is increasing:

- USA: 17% and rising.
- OECD: 9% and rising.
- EU: 10% and rising.

As patients become more demanding and providers' constraints more challenging, cost-effective health solutions and access become a top priority.

mHealth provides answers for major healthcare challenges:

- Improved productivity and efficiency.
- Better utilisation of centralised assets and scarce talent resources.



#### PATIENTS

Aging, more self-guided, more obese, suffering from increasingly complex and chronic diseases



#### PROVIDERS

Rising treatment costs, shortage of talent, growing capacity and budget constraints



#### PAYERS

Increasing pressure to provide quality of care and contain costs



#### GOVERNMENT

Increasing access to care, pressure to provide cost-effective, high-quality outcomes

Source: World Bank, OECD, European Commission




## THE SOLUTION

Mobile Health solutions promise better care and lower costs



On which cost drivers will mHealth have the highest positive impact in the next 5 years?







## MARKET SIZING

Fast growth and adoption of mHealth solutions


### Global mHealth market revenues



### IoT devices in Healthcare



### Physicians offering services via mobile devices




### Health insurance providers paying for services via mobile devices





## THE OPPORTUNITY – mHEALTH MARKET

The Global mHealth enabled care market was worth \$17.2 Billion in 2016




Source: Prost & Sullivan, Clinical mHealth Growth Opportunities, June 2016

The bulk of the global revenues come from services for diagnostic, monitoring, chronic disease management, and ageing applications. The fastest growing segments have been mobile tools and healthcare apps, which have grown at **26%** and 14% cumulative annual growth rate (CAGR) respectively between 2013 to 2016.

### mHEALTH WILL HAVE THE HIGHEST IMPACT ON REDUCING COSTS FOR READMISSION AND DURATION OF STAY IN HOSPITAL


On which cost drivers will mHealth have the highest positive impact in the next 5 years?



Copyright research2guidance 2016  
Source: research2guidance - mHealth App Developer Economics study 2016, n=2600

### REMOTE MONITORING IS NOW THE APP CATEGORY WITH THE GREATEST MARKET POTENTIAL RATING IN THE NEXT 5 YEARS

Which mHealth app categories will offer the highest market potential in the next 5 years?



Copyright research2guidance 2016  
Source: research2guidance - mHealth App Developer Economics study 2016, n=2600



A photograph of a male doctor in a white lab coat with a stethoscope, and a woman with long blonde hair, both looking at a small mobile device held by the doctor. The image is overlaid with a semi-transparent teal filter. A large white number '3' is positioned in the upper center, and a horizontal dotted line is below it.

3

PRODUCT SUITE





## PRIZMA SENSORS

Simply place the Prizma sensors on your smartphone and start taking tests



## PRIZMA MEDICAL APP

The Prizma app is always with you on your smartphone. You can download it from the Apple App Store™ and Google Play™



## USERS PORTAL

Easily view and share your medical test results and history



**COMPLETE SOLUTION**



## FUNCTIONALITY PRODUCT

High-quality sensors implement the following functions:



Temperature



Spo2



Heart Rate



Stress



ECG

### UNIVERSAL COVER



Standalone Prizma with same product functionalities – communicating with each smartphone

Sensors module

Universal Cover

### CUSTOMIZED PRIZMA



**Module:** identical for all smartphones

**Case:** designed according to a specific smartphone model

**Commercial Smartphone**



## PRIZMA REPORT

Share your results





## GMP – BETTER DECISIONS, BEAT BY BEAT

### GMP COMPREHENSIVE VITAL SIGNS MONITORING SYSTEM



#### Small, light and powerful **HARDWARE**

Continuous real-time monitoring of core vital signs: ECG, HR, SpO2, Temp and Body Position



#### Complete 24/7/365 **MONITORING**



#### Leading edge **SOFTWARE**

Cloud-based patient diagnostics




#### Actionable clinical **REPORTING**





## GMP – BETTER DECISIONS, BEAT BY BEAT

**GMP PROVIDES A REAL-TIME VITAL SIGN MONITORING SYSTEM, EASING DECISION-MAKING FOR ENHANCED PATIENT CARE.**



- 1** GMP monitors patient and transmits via 4G/WiFi to the G Medical Innovations Cloud
- 2** The Cloud transmits data to Monitoring Center 24/7/365, analytics and diagnostics compiled as a complete report
- 3** Clinically relevant reports are sent directly to physician
- 4** Physician consults directly with their patient



## GMP – BETTER DECISIONS, BEAT BY BEAT

### PUBLISHED CLINICAL STUDIES CONFIRM...



#### **Single Lead Devices are Inferior to Multiple Lead Systems**

In general, the information provided by the Holter monitors additional 2ECG leads are obvious advantage for both automatic algorithm analysis and physician interpretation. Specifically, 3-lead recordings allow for the detection of arrhythmia events characterized by a shift in electrical axis that can be missed by single lead recording.

The Holter monitor (multiple leads) detected 60 arrhythmia events compared with 52 arrhythmia events by the adhesive patch monitor (single lead).

(iRhythm Study) The American Journal of Medicine, Vol 127, No 1, January 2014

#### **7 Days of Continuous Monitoring Detects Over 96% of Arrhythmias**

Although short of the approved 14-day wear time, the median adhesive patch monitor wear time of 11.1 days in this study is likely a sufficient diagnostic window to capture arrhythmia events, because the highest diagnostic yield for arrhythmia detection is usually the first 7 days of ambulatory ECG monitoring. Ambulatory ECG monitoring beyond 7 days often provides only an additional 3.9% of patients with a diagnosis.

Source: Comparison of 24-hour Holter Monitoring with 14-day Novel Adhesive Patch Electrocardiographic Monitoring\*








## MULTIPLE LEADS MEAN GREATER ACCURACY

**GMP PROVIDES UP TO SIX VIEWS OF THE HEART FOR ACCURATE AND TIMELY ALGORITHM RECOGNITION (99.7% AGAINST MIT DATABASE)**

G Medical – ECG Summary Report

G Medical: 3 Lead ECG, 1-6 Lead ECG Capability




## Industry Standard Patch: 1 Lead ECG



Supraventricular Tachycardia

09/20/2017 18:04

Rate: 78 BPM




**Findings:** SINUS RHYTHM-78 BPM WITH A SINGLE EPISODE OF ~10 SEC.RUN OF SUPRA-VENTRICULAR TACHY WITH HR=177



## G MEDICAL – NEXT GENERATION (3-YEAR PLAN)

### EXPANDING VITAL AND BIOMETRIC MONITORING CAPABILITIES





# 4



## BUSINESS MODEL



## BUSINESS MODEL

### PRIZMA

#### Sales of Products

Prizma & Accessories

#### Services Fee Income



Cloud \ Portal



Call Center

#### Channels

##### B2B

- Mobile Operators
- Insurance Companies
- Distributors

##### B2C

- Online Store
- Market Places

### VSMS/GMP

#### Services Income

Per Patient Use

#### Sales of Products

- Patch unit
- Disposables
- System

#### Channels

##### B2B

- Hospital & Clinic
- Home Monitoring



## SYNERGY

PRE- HOSPITALIZATION

HOSPITALIZATION

POST-DISCHARGE


PATIENTS' HEALTHCARE LIFECYCLE






## IDTF USA BUSINESS MODEL

### THE PROCESS




### INCOME BASED ON SERVICE TYPE





## AMBULATORY CARDIAC MONITORING OFFERS SIGNIFICANT OPPORTUNITY


Increased diagnostic yield leads to  
timely diagnosis



Measure	Product Type	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	CAGR ('15-'25)
Market Value (USDM)	Holter Monitors	169	197	231	270	312	355	397	438	476	511	543	12.4%
	Event Recorders	321	321	319	316	311	307	302	299	297	297	298	-0.8%
	Telemetry Devices	282	399	542	701	864	1,020	1,166	1,300	1,421	1,528	1,625	19.1%
	ILRs	236	273	313	366	437	549	711	796	865	920	963	15.1%
	Total	1,008	1,190	1,405	1,653	1,924	2,231	2,577	2,834	3,059	3,256	3,429	13.0%
Market Value (% Growth)	Holter Monitors	—	16.8%	17.3%	16.9%	15.5%	13.7%	11.9%	10.2%	8.7%	7.4%	6.3%	12.4%
	Event Recorders	—	0.0%	-0.6%	-1.0%	-1.4%	-1.5%	-1.4%	-1.0%	-0.7%	-0.2%	0.3%	-0.8%
	Telemetry Devices	—	41.5%	35.7%	29.4%	23.2%	18.1%	14.3%	11.5%	9.3%	7.6%	6.3%	19.1%
	ILRs	—	15.6%	14.6%	17.1%	19.4%	25.6%	29.6%	12.0%	8.6%	6.3%	4.7%	15.1%
	Total	—	18.1%	18.0%	17.7%	16.4%	15.9%	15.5%	10.0%	8.0%	6.4%	5.3%	13.0%



## U.S.A. TELEMETRY DEVICE MARKET (USD) 2015–2025



Measure	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	CAGR ('15-'25)
Market Value (USD M)	282	399	542	701	864	1,020	1,166	1,300	1,421	1,528	1,625	19.1%
Market Value (% Growth)	—	41.5%	35.7%	29.4%	23.2%	18.1%	14.3%	11.5%	9.3%	7.6%	6.3%	19.1%

Source: Millennium Research Group, Inc.


# 5



## MILESTONES




## INVESTMENTS / IPO



Source: Management



## REGULATION, AGREEMENTS / MOU'S (Post Listing)



Source: Management

Commercialisation





THANK YOU

# APPENDICES



## MARKET




CHINA



## CHINA'S HEALTH CARE CHALLENGES

Being the world's largest economy and representing almost 20% of global population, China is facing a life-time challenge providing health care for its people.







## CHINA'S RISING POPULATION & HEALTH EXPENDITURE

- In view of rapidly rising population, China is increasingly facing challenges in efficiently managing its health care systems.
- As industrialization and rising living standards have led to a huge increase in average life expectancy, demand for medical services is expected to increase drastically.
- In 2014, health expenditure in China reached RMB 3.5 trillion, quadrupling its 2004 value with a CAGR of 17.2%.
- In 2014, health care expenses accounted for 5.5% of Gross Domestic Product (GDP).

Annual Health Expenditure 2004-2014  
In RMB, billion (% of GDP)



Annual Average Medical Expenditures in  
Different Age Groups  
In RMB, billion






## AFFORDABILITY OF HEALTH CARE & CHRONIC ILLNESSES

Chinese personal medical spending as % of total medical expenses has been declining even though the monetary value has been growing steadily. This is due to an increase in government expenditure on medical expenses due to a westernization process and the renewed understanding that medical expenses present a great burden for the majority of Chinese population. This trend is expected to continue into the future.

The increase in the number of elderly Chinese patients goes along with an increase in mortality and an increasing prevalence of chronic illnesses and cardiovascular diseases, this leads to increasing costs of treatment and longer recovery times.

- 260M people are diagnosed with chronic diseases each year.
- Accounting for 85% of deaths.
- Projected annual cardiovascular events are predicted to increase by 50% between 2010 and 2030.

Medical Expenses 2006-2011  
In 100 million RMB




Sources: Brookings, Statista

Incidences of Chronic Diseases in China

Heart Disease	Digestive disease	Cerebrovascular disease	Cancers	Arthritis	Diabetes
18.9%	23.8%	10.2%	2.2%	11.6%	12.4%

Hospitalization Costs of Cardiovascular Disease in China





## FACTORS INFLUENCING CHINA HEALTHCARE


### Factors that need improvement

- Large hospitals are overbooked due to the belief that community health centers do not have the resources nor the knowledge to treat patient on a sustainable level
- Lack of affordable healthcare in rural communities due to the abolishment of rural health clinics that were replaced with private clinics
- Lack of funds in the rural communities to gain access to large hospitals
- Besides the cities where the employers pays health insurance most of the population cannot access its benefits due to the nature of their working situation

### Factors benefitting healthcare


- High technology adoption rates with over 59% are willing to adopt new technologies in their nascent stage

### Occupancy rate by type of hospital



### Medical Staff Comparison

Per 1000 population





TELCOS





## MHEALTH PROVIDES MOBILE OPERATORS WITH THE OPPORTUNITY TO INCREASE ARPU, ACQUIRE NEW SUBSCRIBERS AND REDUCE CHURN RATE

Chronic disease  
management and post acute  
care monitoring services  
alone will comprise

**USA\$10.7 billion**

in mHealth revenue by 2017


By 2017, the global mHealth  
market value is expected to  
be worth

**USA\$ 26 billion**




## THE RAPID ADOPTION OF SMARTPHONES AND TABLET DEVICES HAS TRIGGERED A SIGNIFICANT GROWTH IN THE USE OF MHEALTH APPS

**Over 500 million**  
people are expected to  
use health care mobile  
applications on their  
smartphones



**~100K**  
Mobile apps related to  
health & fitness

**4 million free &  
300K paid** downloads per day  
generated by the top 10  
mHealth apps



**50%**  
of smartphone users  
will download mobile  
health apps by 2017



# REGULATION STATUS



## Regulatory Status

### PRIZMA Status

FDA, CE, TGA Granted (CFDA pending)

- Submitted to the FDA the file for Over the Counter (OTC) approval

### VSMS/GMP Status

- **Extended Holter**
  - CE Holter approved
  - FDA – review in progress
- **Auto-Detect/Auto-Send**
  - Review in progress



# PATENTS STATUS



## G Medical Patents

Title	Filing Date	Status	Application Num	Attorney Ref	Type
JACKET FOR MEDICAL MODULE	30/01/2018	FILED		8947-CN	Foreign
	22/08/2017	Pending	PCT/IL2017/050939	8947-PC	PCT
REMOTE MONITORING OF A PERSON AND AN AUTOMATIC DISTRIBUTION OF PRESCRIPTION DRUGS	24/10/2017	Pending	PCT/IL2017/051162	8953-PC	PCT
SYSTEMS AND METHODS FOR VITAL SIGNS MONITORING WITH EAR PIECE	25/07/2017	Pending	112017015881 7	8967-BR	Foreign
	10/08/2017	Pending	16742887.9	8967-EP	Foreign
	25/07/2017	Pending	2017-557516	8967-JP	Foreign
	25/07/2017	Pending	10-2017-7023630	8967-KR	Foreign
	26/01/2016	Published	PCT/IL2016/050084	8967-PC	PCT
	12/10/2017	Pending	2017124408	8967-RU	Foreign
DEVICE, SYSTEM AND METHOD FOR NONINVASIVELY MONITORING PHYSIOLOGICAL PARAMETERS	02/08/2016	Published	15/225,849	8967-US	Non-Provisional
	25/10/2017	Pending	2016295720	8968-AU	Foreign
		In process		8968-BR	Foreign
	08/08/2017	Pending	2.0168E+11	8968-CN	Foreign
	29/01/2018	Pending	16832414.3	8968-EP	Foreign
	29/01/2018	Pending		8968-JP	Foreign
		In process		8968-KR	Foreign
	16/05/2016	Pending	PCT/IL2016/050516	8968-PC	PCT
		Unfiled		8968-RU	Foreign
SYSTEMS AND METHODS FOR VITAL SIGNS MONITORING WITH EAR PIECE	31/03/2016	Published	15/026,258	8968-US	Non-Provisional
METHOD AND SYSTEM FOR LOCATING A DEFIBRILLATOR	10/02/2017	Pending - being converted	62/457,185	8981-USP	Provisional
METHOD AND SYSTEM FOR OBTAINING PHYSICAL CONDITION THAT LEAD TO A DEFIBRILLATOR COUNTERSHOCK	5/09/2017	Pending	62/562,621	9046-USP	Provisional
HEALTH MONITORING DEVICE THAT INCLUDES A COMPACT OXIMETER	30/01/2018	FILED		9093-CN	Foreign
	13/11/2017	Pending	62/584,984	9093-USP	Provisional



# PRIZMA COMPETITION



## PRIZMA COMPETITION REVIEW

Product	Tests	Regulatory Approvals	Comments
G Medical – Prizma Medical Smartphone	Suite of test : 1 lead ECG + heartrate+ Spo2 + temperature + Stress: level detection of 19 Arrhythmias	CE and FDA approved  (CFDA pending)	Three configurations: 1. Customized case 2. Standalone 3. Full kit with low cost mobile
Garmin Vivoactive HR	GPS Smartwatch with wrist-based heart rate monitoring. The device can also log steps, floors climbed, intensity minutes and sleep quality. Connect to App	No regulatory approvals	
Quardio – QuardioCore	Wireless Bluetooth waterproof ECG monitor: EKG/ECG Skin Temperature Heart Rate Heart Rate Variability Activity Tracking Respiratory Rate	No regulatory approvals	Need to be worn for at all time for detection Only iOS compatible





## PRIZMA COMPETITION REVIEW (Cont.)

Product	Tests	Regulatory Approval	Comments
AliveCore – Kardia Mobile	1 lead ECG (not a suite of tests) - Detect normal heart rhythm or AFib	FDA approved	No service Single test – limited audience Portable
Azoi – Kito+	Suite of tests: ECG, blood oxygen levels, skin temperature and respiration rate	No regulatory approvals	Case placed over the mobile.
WiWe	Suite of tests: ECG parameters, + Arrhythmias stroke and cardiac arrest risk assessment + SPO2 + Wellness features (such as BMI and steps)	CE Approved	New comer. Portable
Polar - Polar H10	Heart rate sensor which comes as a chest strap. Waterproof (suitable for swimming) and compatible with top fitness apps	No regulatory approvals	Wellness device